Olatoyosi Odenike to Mitogen-Activated Protein Kinase Kinases
This is a "connection" page, showing publications Olatoyosi Odenike has written about Mitogen-Activated Protein Kinase Kinases.
Connection Strength
0.582
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.452
-
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
Score: 0.130